Annual General Meeting of June 28, 2013

• All proposed resolutions were voted according to management’s recommendations
• Pr. Michael Caligiuri was appointed as a new member of the Supervisory Board

Innate Pharma (Euronext Paris: FR0010331421 – IPH) announces that during its Annual General Meeting (“AGM”) which took place on June 28, 2013, in Marseille, France, a number of 21,278,689 votes were expressed out of a total of 38,055,614 shares with voting rights, representing a quorum of 55.9%. All resolutions were voted in accordance with the management’s recommendations. Details of the votes are available on Innate Pharma’s website, in the investors section.

During the AGM, Pr. Michael Caligiuri, CEO of The James Cancer Hospital and Director of the Comprehensive Cancer Center at The Ohio State University, was appointed as a new member of the Supervisory Board.